Check 35,000+ stocks against 26 valuation models and 37 quality factors

Gufic Biosciences Limited (509079) fair value: what the stock is really worth

As of Oct 1, 2026: fair value of Gufic Biosciences Limited ₹182, price ₹418, upside -56.4%, quality 48 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? No
Add to watchlist

Healthcare · IN · ISIN INE742B01025

GB Broad data Sep 24, 2026

Gufic Biosciences Limited

509079 · BSE

Weakest SetupStrongly overvalued and low quality.

!Fair value ₹182.30 · Strongly overvalued (−56.4%)

!Quality 48/100

✓Healthy Growth (revenue 5y +18.0 %/yr)

!Thin margins · 6.9% net margin (TTM)

✓Low debt

!Moderate moat 57/100

26 models, one by oneBear ₹81.58 to bull ₹246.10 Growth analysisrevenue history, year by year Quality 48/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Gufic Biosciences Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range ₹172.13 – ₹486.87 · fair‑value band ₹81.58 – ₹246.10 · the ₹418.20 price screens above the ₹182.30 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Gufic Biosciences Limited engages in the manufacture and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India. It manufactures APIs and bulk drugs, such as antifungals, anaesthetics, and immuno suppressants, as well as intermediates for antifungals. The company also manufactures lyophilized injections, which include antibiotic, antifungal, cardiac, infertility, antiviral, and proton-pump inhibitor segments. In addition, it offers spark, criti care, and ferticare pharmaceutical products; and herbal and personal care products. The company supplies its products to hospital chains and medical facilities. It also exports its products. The company was founded in 1970 and is based in Mumbai, India.

Stock analysis

Gufic Biosciences Limited (509079) currently trades at ₹418.20, while our model-based Fair Value estimate is ₹182.30, 56.4% below the price, so the stock looks overvalued today.

Valuation

Bull case: the Growth Earnings group reads highest at a median of ₹220.60 per share, and 0 of the 26 models we run sit above the ₹418.20 price.

Bear case: the Asset-Based group reads lowest at ₹51.74, and 26 of the 26 models stay below the price. Evidence for this calculation is high.

Scenario range: ₹81.58 (bear) to ₹246.10 (bull), the price of ₹418.20 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Gufic Biosciences Limited reported revenue of ₹8.2B in FY2025 versus ₹4.9B in FY2021, a compound +13.9%/yr. Reported net income was ₹696M in FY2025, compounding +12.0%/yr from FY2021.

Key figures

Market cap ₹7.0B (≈ $72.2M) · P/E ratio 77.1 · P/S ratio 6.55 · EPS (TTM) ₹3.13 · Dividend yield 0.0% · Net margin 8.5% · Return on equity 25.2% · Return on assets (EBIT) 15.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).

What moves the price

The share trades about 6% below its 52-week high and 54% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −10% fair-value upside, at −56%, 509079 screens richer than that median.

Fair Value models

Bear ₹81.58 Fair Value ₹182.30 Bull ₹246.10

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then (₹3.08 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

Residual Income ₹63.31 ₹68.94 ₹83.98 76

FCF DCF ₹46.59 ₹84.65 ₹168.64 75

Growth DCF ₹44.24 ₹87.12 ₹143.96 75

All 26 models by family

DCF Models

FCF DCF ₹46.59 ₹84.65 ₹168.64 75

Owner Earnings ₹4.36 ₹20.41 ₹46.29 68

5Y Revenue Exit ₹92.32 ₹202.05 ₹361.68 69

5Y EBITDA Exit ₹115.11 ₹252.95 ₹438.78 71

5Y P/E Exit ₹92.71 ₹202.91 ₹338.64 67

10Y Revenue Exit ₹68.40 ₹158.06 ₹314.24 62

10Y EBITDA Exit ₹85.60 ₹191.46 ₹373.92 64

10Y P/E Exit ₹72.44 ₹158.62 ₹296.41 60

Earnings-Based

Graham-Dodd ₹60.85 ₹364.53 ₹508.02 63

Lynch FV ₹103.86 ₹148.37 ₹192.89 61

PEG = 1.0 ₹103.86 ₹148.37 ₹192.89 57

EPV ₹81.14 ₹92.77 ₹102.21 74

Dividend Discount

Gordon GGM ₹0.9000 ₹1.50 ₹1.95 68

DDM Multi-Stage ₹0.9000 ₹1.43 ₹1.62 67

Multiples

P/E Multiple ₹147.66 ₹196.88 ₹246.10 63

P/S Multiple ₹114.10 ₹152.13 ₹190.16 58

P/B Multiple ₹114.10 ₹152.13 ₹190.16 55

EV/EBIT ₹176.44 ₹240.51 ₹304.58 66

EV/EBITDA ₹170.94 ₹233.18 ₹295.41 67

EV/Revenue ₹121.42 ₹180.21 ₹239.01 53

Asset-Based

NCAV (Graham) ₹38.61 ₹51.74 ₹77.23 54

Growth DCF

Growth DCF ₹44.24 ₹87.12 ₹143.96 75

Rev-Margin DCF ₹92.32 ₹196.23 ₹342.54 69

Economic Profit

Residual Income ₹63.31 ₹68.94 ₹83.98 76

ROIC Compounder ₹83.22 ₹108.72 ₹134.53 72

Growth Earnings

Growth-Adj P/E ₹154.42 ₹220.60 ₹286.77 67

Open the full fair value analysis →

Notify me when 509079 reaches fair value

Put 509079 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 48/100

Of which business quality 48 · Market factors (momentum, volatility) 63

Profitability 49

Margins and returns on capital today

Quality Growth 39

Are margins and returns improving?

Cashflow 49

Earnings quality: real cash, not paper profit

Fin. Strength 48

Balance sheet, leverage, solvency risk

Investment 20

Disciplined investing over empire-building

Low Volatility 49

Calm price path (market factor)

Momentum 69

Price trend over the last 3–12 months (market factor)

52W Momentum 66

Distance to the 52-week high (market factor)

Net Issuance 76

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 90/100

Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Revenue growth 1 year

+1.6%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+1.7%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+18.0%

Start year 2020 (pandemic). Over 10 years: +18.4% a year

Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+18.8%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.

+19.8%

Earnings growth per share plus dividend.

Earnings per share, growth per year+19.8%

Dividend (yield on the price)0.0%

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.10% → 14%

509079 screens overvalued: fair value 56% below the price. Compare with Anuh Pharma Limited →

Compare Gufic Biosciences Limited with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Drugs - Generic” was too small, so the broader sector is used.)Health Care · 2472 stocks

Beats the sector median on 7/13 measures

A mixed picture versus its sector peers.

Valuation

Quality Score 48 · Below median

Fair Value upside −56.7% · Below median

Profitability

Return on equity (TTM) 25.2% · Top 25%

Return on assets 7.2% · Top 25%

Net margin (TTM) 6.9% · Above median

Operating margin (TTM) 11.0% · Above median

Growth and dividend

Revenue growth 42.5% · Top 25%

Dividend yield (TTM) 0.0% · Bottom 25%

Balance sheet

Debt / equity 0.22× · Above median

Valuation Multiplesvs Health Care median · lower = cheaper

P/E (TTM) 77.1× · Priciest 25%

P/B 1.16× · Cheaper than median

P/S (TTM) 1.96× · Cheaper than median

EV/EBITDA 18.1× · Pricier than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drugs - Generic stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Anuh Pharma Limited 506260	₹86.88	₹30.19	−65%
Eli Lilly and Company LLY	$1,157	$749.08	−35%
Johnson & Johnson, JNJ	$264.74	$168.85	−36%
AbbVie Inc ABBV	$261.59	$259.62	−1%
Roche Holding RO	CHF 375.20	CHF 326.56	−13%
Merck & Co MRK	$143.81	$129.26	−10%
UnitedHealth Group UNH	$367.08	$295.49	−20%
Novartis AG NOVN	CHF 118.06	CHF 121.90	+3%
Thermo Fisher Scientific Inc TMO	$675.05	$686.04	+2%
Amgen Inc AMGN	$421.51	$463.66	+10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Gufic Biosciences Limited · Fair Value
₹182.30 −56%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/509079" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Gufic Biosciences Limited · Fair Value</span><br><b style="font-size:20px">₹182.30</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−56%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Gufic Biosciences Limited Fair Value". https://www.fairvalue-calculator.com/stock/509079

Frequently asked questions

Is Gufic Biosciences Limited (509079) overvalued or undervalued?

As of Sep 24, 2026, our model estimates a fair value of ₹182.30 versus a price of ₹418.20, about −56% upside (overvalued).

What is the fair value of 509079?

Our model-based fair value for Gufic Biosciences Limited is ₹182.30 (as of Sep 24, 2026), built from audited fundamentals. The current price: ₹418.20.

What is the quality score of 509079?

Gufic Biosciences Limited has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Gufic Biosciences Limited (509079)?

Our model-based price target is the fair value of ₹182.30 (as of Sep 24, 2026) from 26 valuation models. Cautious scenario ₹81.58, optimistic scenario ₹246.10. It is a calculation from audited fundamentals, not an analyst target.

What is the Gufic Biosciences Limited stock forecast for 2026?

Our models put fair value at ₹182.30, about −56% upside versus a price of ₹418.20 (overvalued). Cautious scenario ₹81.58, optimistic scenario ₹246.10. The calculation is refreshed regularly with new filings.

What is the revenue of Gufic Biosciences Limited (509079)?

Gufic Biosciences Limited reported trailing-twelve-month revenue of about ₹3.5B (latest available figure, as of Sep 24, 2026).

Does Gufic Biosciences Limited pay a dividend?

Gufic Biosciences Limited currently shows a dividend yield of about 0.04% relative to its recent price (as of Sep 24, 2026).

What is the intrinsic value of Gufic Biosciences Limited (509079)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Gufic Biosciences Limited it is ₹182.30 per share (as of Sep 24, 2026), against a price of ₹418.20. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).

Is Gufic Biosciences Limited stock overvalued or undervalued in 2026?

As of Sep 24, 2026, 509079 trades above its calculated fair value: price ₹418.20, fair value ₹182.30, a gap of about −56% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 509079?

No. The price is what the market pays today (₹418.20); the fair value is what the company's own numbers justify (₹182.30). For Gufic Biosciences Limited the two are ₹235.90 per share apart. That gap is exactly why we show both numbers side by side.

How much is Gufic Biosciences Limited worth?

The market values Gufic Biosciences Limited at about ₹7.0B (market capitalisation, as of Sep 24, 2026). Per share that is ₹418.20; our models calculate a fair value of ₹182.30 per share.

What do the bullish and bearish scenarios say about 509079?

Our models span a range for Gufic Biosciences Limited: cautious scenario ₹81.58, base ₹182.30, optimistic ₹246.10 per share (as of Sep 24, 2026, price ₹418.20). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of 509079?

Gufic Biosciences Limited trades at a price-to-earnings ratio of 77.1 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹182.30 is built from several models across several years. Other multiples: P/B 1.2, P/S 2.0, EV/EBITDA 18.1.

How solid is the balance sheet of Gufic Biosciences Limited (509079)?

Balance-sheet figures for Gufic Biosciences Limited (as of Sep 24, 2026): return on equity 25.2%, debt of 0.22 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.

How far is 509079 from its 52-week high?

Gufic Biosciences Limited trades at ₹418.20, about 6% below its 52-week high of ₹446.95 and 54% above the low of ₹271.05 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹182.30 is for.

Which stocks are comparable to Gufic Biosciences Limited?

From the same area (Healthcare) we also value Anuh Pharma Limited, Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Gufic Biosciences Limited stock attractive at the current price?

The data as of Sep 24, 2026: price ₹418.20, calculated fair value ₹182.30 (−56%), Quality Score 48/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 509079 calculated?

We run Gufic Biosciences Limited through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹182.30, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.5 % above its aggregate fair value. Gufic Biosciences Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Gufic Biosciences Limited (509079)?

The closing price on Oct 1, 2026 was ₹418.20. Our model-based fair value is ₹182.30, about −56% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Gufic Biosciences Limited right now?

The price sits above even our optimistic bull case (₹246.10). The favourable scenario is already priced in. The model range is unusually wide (₹81.58 to ₹246.10). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (48/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Gufic Biosciences Limited

How large is the market capitalisation of Gufic Biosciences Limited (509079)?

The market capitalisation of Gufic Biosciences Limited is ₹7.0B (≈ $72.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Gufic Biosciences Limited (509079)?

The price-to-sales ratio of Gufic Biosciences Limited is 6.55 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Gufic Biosciences Limited (509079)?

Earnings per share at Gufic Biosciences Limited are ₹3.13 (price ÷ EPS = P/E 77.1). Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of Gufic Biosciences Limited (509079)?

The dividend yield of Gufic Biosciences Limited is 0.0% (payout 5.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of Gufic Biosciences Limited (509079)?

The net margin of Gufic Biosciences Limited is 8.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Gufic Biosciences Limited (509079)?

The return on equity (ROE) of Gufic Biosciences Limited is 25.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Gufic Biosciences Limited (509079)?

On an EBIT basis the return on assets of Gufic Biosciences Limited is 15.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Gufic Biosciences Limited (509079)?

The operating margin of Gufic Biosciences Limited is 11.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Gufic Biosciences Limited (509079)?

Revenue at Gufic Biosciences Limited is growing +42.5% versus a year earlier (3y avg +1.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Gufic Biosciences Limited (509079)?

Earnings per share at Gufic Biosciences Limited are growing +282% versus a year earlier. How much earnings per share grew versus a year earlier.

Free · no account needed

Watch Gufic Biosciences Limited in the live analysis

One click puts Gufic Biosciences Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.